HC Wainwright Raises AC Immune's Q2 2025 Earnings Outlook

Summary

HC Wainwright raised the Q2 2025 earnings expectations for AC Immune, predicting earnings per share to be $0.21, up from the previous $0.22 forecast. The firm maintains a ‘buy’ rating with a target price of $12.00. AC Immune’s stock opened at $1.72, with institutional investors holding 51.36% of shares, indicating strong interest. AC Immune had reported EPS of $0.21 last quarter, exceeding expectations.Market Beat

Impact Analysis

This is a company-level event as it directly pertains to AC Immune’s financial performance and stock evaluation by HC Wainwright. The upward revision in earnings expectations suggests potential positive sentiment among investors and analysts, possibly leading to increased stock purchases or a rise in stock price. The ‘buy’ rating and target price of $12.00 suggest confidence in growth potential, which may attract more investors. Risks include market volatility and competitive pressures in biotech. Opportunities include taking a position in AC Immune if it aligns with an investor’s strategy and risk tolerance.Market Beat